Infliximab attenuates inflammatory osteolysis in a model of periodontitis in Wistar rats

Experimental Biology and Medicine

Volumn 239, Issue 4, 2014, Pages 442-453

  Gonçalves, Davi C ^a   Evangelista, Rakel C ^a   da Silva, Rafael R ^a   Santos, Maria J S ^a   Silva Jr , Francisco S ^a   Aragão, Karoline S ^a   Brito, Gerly A C ^a   Lucena, Herene B M ^a   Leitão, Renata C ^a   Oriá, Reinaldo B ^a  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

Author keywords

inflammation; Infliximab; periodontitis; RANK; TNF alpha

Indexed keywords

INFLAMMATION; INFLIXIMAB; PERIODONTITIS; RANK; TNF-ALPHA;

ALVEOLAR BONE LOSS; ANIMALS; ANTIBODIES, MONOCLONAL; COLLAGENASES; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-1BETA; OSTEOLYSIS; PERIODONTITIS; PEROXIDASE; RATS, WISTAR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84898984672     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370213520114     Document Type: Article

References (50)

1. Papapanou PN.Epidemiology of periodontal diseases: an update.J Int Acad Periodontol. 1999;1:110-6.
2. Kornman KS.Mapping the pathogenesis of periodontitis: a new look.J Periodontol. 2008;79:1560-8.
3. Soukos NS,Goodson JM.Photodynamic therapy in the control of oral biofilms.Periodontol 2000. 2011;55:143-166.
4. Armitage GC.Development of a classification system for periodontal diseases and conditions.Ann Periodontol. 1999;4:1-6.
5. Arweiler NB,Pietruska M,Skurska A,Dolinska E,Pietruski JK,Blas M,Auschill TM,Sculean A.Nonsurgical treatment of aggressive periodontitis with photodynamic therapy or systemic antibiotics. Three-month results of a randomized, prospective, controlled clinical study.Schweiz Monatsschr Zahnmed. 2013;123:532-44.
6. Bartold PM,Cantley MD,Haynes DR.Mechanisms and control of pathologic bone loss in periodontitis.Periodontol 2000. 2010;53:55-69.
7. Azuma Y,Kaji K,Katogi R,Takeshita S,Kudo A.Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts.J Biol Chem. 2000;275:4858-64.
8. Fuller K,Murphy C,Kirstein B,Fox SW,Chambers TJ.TNFalpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL.Endocrinology. 2002;143:1108-18.
9. Gravallese EM.Bone destruction in arthritis.Ann Rheum Dis. 2002;61:ii84-6.
10. Khosla S.Minireview: the OPG/RANKL/RANK system.Endocrinology. 2001;142:5050-5.
11. Dougall WC,Glaccum M,Charrier K,Rohrbach K,Brasel K,De ST,Daro E,Smith J,Tometsko ME,Maliszewski CR,Armstrong A,Shen V,Bain S,Cosman D,Anderson D,Morrissey PJ,Peschon JJ,Schuh J.RANK is essential for osteoclast and lymph node development.Genes Dev. 1999;13:2412-24.
12. Odgren PR,Kim N,MacKay CA,Mason-Savas A,Choi Y,Marks SC.The role of RANKL (TRANCE/TNFSF11), a tumor necrosis factor family member, in skeletal development: effects of gene knockout and transgenic rescue.Connect Tissue Res. 2003;44:264-71.
13. Leibbrandt A,Penninger JM.RANK/RANKL: regulators of immune responses and bone physiology.Ann N Y Acad Sci. 2008;1143:123-50.
14. Kao DW,Fiorellini JP.Regenerative periodontal therapy.Front Oral Biol. 2012;15:149-59.
15. Perdriger A.Infliximab in the treatment of rheumatoid arthritis.Biologics. 2009;3:183-91.
16. Tracey D,Klareskog L,Sasso EH,Salfeld JG,Tak PP.Tumor necrosis factor antagonist mechanisms of action: a comprehensive review.Pharmacol Ther. 2008;117:244-79.
17. Eissner G,Kirchner S,Lindner H,Kolch W,Janosch P,Grell M,Scheurich P,Andreesen R,Holler E.Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages.J Immunol. 2000;164:6193-8.
18. Mayer Y,Balbir-Gurman A,Machtei EE.Anti-tumor necrosis factor-alpha therapy and periodontal parameters in patients with rheumatoid arthritis.J Periodontol. 2009;80:1414-20.
19. Bezerra MM,de LV,Alencar VB,Vieira IB,Brito GA,Ribeiro RA,Rocha FA.Selective cyclooxygenase-2 inhibition prevents alveolar bone loss in experimental periodontitis in rats.J Periodontol. 2000;71:1009-14.
20. Page RC,Schroeder HE.Current status of the host response in chronic marginal periodontitis.J Periodontol. 1981;52:477-91.
21. Lima-Junior RC, Figueiredo AA, Freitas HC, Melo ML, Wong DV, Leite CA, Medeiros RP, Marques-Neto RD, Vale ML, Brito GA, Oria RB, Souza MH, Cunha FQ, Ribeiro RA. Involvement of nitric oxide on the pathogenesis of irinotecan-induced intestinal mucositis: role of cytokines on inducible nitric oxide synthase activation. Cancer Chemother Pharmacol 2011:931-42.
22. Azoubel MC,Menezes AM,Bezerra D,Oria RB,Ribeiro RA,Brito GA.Comparison of etoricoxib and indomethacin for the treatment of experimental periodontitis in rats.Braz J Med Biol Res. 2007;40:117-25.
23. Leitao RF,Ribeiro RA,Chaves HV,Rocha FA,Lima V,Brito GA.Nitric oxide synthase inhibition prevents alveolar bone resorption in experimental periodontitis in rats.J Periodontol. 2005;76:956-63.
24. Monaco C,Rossi E,Milazzo D,Citterio F,Ginnetti F,D'Onofrio G,Cianflone D,Crea F,Biasucci LM,Maseri A.Persistent systemic inflammation in unstable angina is largely unrelated to the atherothrombotic burden.J Am Coll Cardiol. 2005;45:238-43.
25. Huang H,Zhao N,Xu X,Xu Y,Li S,Zhang J,Yang P.Dose-specific effects of tumor necrosis factor alpha on osteogenic differentiation of mesenchymal stem cells.Cell Prolif. 2011;44:420-7.
26. Gilbert LC,Chen H,Lu X,Nanes MS.Chronic low dose tumor necrosis factor-alpha (TNF) suppresses early bone accrual in young mice by inhibiting osteoblasts without affecting osteoclasts.Bone. 2013;56:174-83.
27. Lima V,Vidal FD,Rocha FA,Brito GA,Ribeiro RA.Effects of tumor necrosis factor-alpha inhibitors pentoxifylline and thalidomide on alveolar bone loss in short-term experimental periodontal disease in rats.J Periodontol. 2004;75:162-8.
28. Kawamura H,Arai M,Togari A.Inhibitory effect of chlorpromazine on RANKL-induced osteoclastogenesis in mouse bone marrow cells.J Pharmacol Sci. 2011;117:54-62.
29. de LV,Bezerra MM,de Menezes Alencar VB,Vidal FD,da Rocha FA,de Castro Brito GA,de Albuquerque RR.Effects of chlorpromazine on alveolar bone loss in experimental periodontal disease in rats.Eur J Oral Sci. 2000;108:123-9.
30. Akman SA,Arikan C,Sozen G,Ozturk C,Yagci RV.Infliximab treatment of pediatric refractory Crohn's disease: a case report.Turk J Gastroenterol. 2006;17:133-6.
31. Van Dyke TE,Serhan CN.Resolution of inflammation: a new paradigm for the pathogenesis of periodontal diseases.J Dent Res. 2003;82:82-90.
32. Becker AK. Interpretación del hemograma. Rev Chilena Ped 2001;72:460-5.
33. Schwarz BC, Hoven RV, Schwendenwein I. Diagnostic value of the neutrophil myeloperoxidase index in horses with systemic inflammation. Vet J 2011:72-8.
34. Pers JO,Saraux A,Pierre R,Youinou P.Anti-TNF-alpha immunotherapy is associated with increased gingival inflammation without clinical attachment loss in subjects with rheumatoid arthritis.J Periodontol. 2008;79:1645-51.
35. Boyce BF,Li P,Yao Z,Zhang Q,Badell IR,Schwarz EM,O'Keefe RJ,Xing L.TNF-alpha and pathologic bone resorption.Keio J Med. 2005;54:127-31.
36. Wei S,Kitaura H,Zhou P,Ross FP,Teitelbaum SL.IL-1 mediates TNF-induced osteoclastogenesis.J Clin Invest. 2005;115:282-90.
37. Boyce BF,Xing L.Biology of RANK, RANKL, and osteoprotegerin.Arthritis Res Ther. 2007;9:S1-S1.
38. Poubelle PE,Chakravarti A,Fernandes MJ,Doiron K,Marceau AA.Differential expression of RANK, RANK-L, and osteoprotegerin by synovial fluid neutrophils from patients with rheumatoid arthritis and by healthy human blood neutrophils.Arthritis Res Ther. 2007;9:R25-R25.
39. Boyce BF,Xing L.Functions of RANKL/RANK/OPG in bone modeling and remodeling.Arch Biochem Biophys. 2008;473:139-46.
40. Rincon JC,Young WG,Bartold PM.The epithelial cell rests of Malassez-a role in periodontal regeneration?.J Periodontal Res. 2006;41:245-52.
41. Hasegawa N,Kawaguchi H,Ogawa T,Uchida T,Kurihara H.Immunohistochemical characteristics of epithelial cell rests of Malassez during cementum repair.J Periodontal Res. 2003;38:51-6.
42. Kook SH,Jang YS,Lee JC.Human periodontal ligament fibroblasts stimulate osteoclastogenesis in response to compression force through TNF-alpha-mediated activation of CD4+ T cells.J Cell Biochem. 2011;112:2891-901.
43. Kato R,Ishihara Y,Kawanabe N,Sumiyoshi K,Yoshikawa Y,Nakamura M,Imai Y,Yanagita T,Fukushima H,Kamioka H,Takano-Yamamoto T,Yamashiro T.Gap-junction-mediated communication in human periodontal ligament cells.J Dent Res. 2013;92:635-40.
44. Wei S,Siegal GP.Mechanisms modulating inflammatory osteolysis: a review with insights into therapeutic targets.Pathol Res Pract. 2008;204:695-706.
45. Dahan M,Nawrocki B,Elkaim R,Soell M,Bolcato-Bellemin AL,Birembaut P,Tenenbaum H.Expression of matrix metalloproteinases in healthy and diseased human gingiva.J Clin Periodontol. 2001;28:128-36.
46. Kinane DF,Darby IB,Said S,Luoto H,Sorsa T,Tikanoja S,Mantyla P.Changes in gingival crevicular fluid matrix metalloproteinase-8 levels during periodontal treatment and maintenance.J Periodontal Res. 2003;38:400-4.
47. Lagervall M,Jansson L,Bergstrom J.Systemic disorders in patients with periodontal disease.J Clin Periodontol. 2003;30:293-9.
48. Havemose-Poulsen A,Westergaard J,Stoltze K,Skjodt H,Danneskiold-Samsoe B,Locht H,Bendtzen K,Holmstrup P.Periodontal and hematological characteristics associated with aggressive periodontitis, juvenile idiopathic arthritis, and rheumatoid arthritis.J Periodontol. 2006;77:280-8.
49. Keane J,Gershon S,Wise RP,Mirabile-Levens E,Kasznica J,Schwieterman WD,Siegel JN,Braun MM.Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.N Engl J Med. 2001;345:1098-104.
50. Papp KA,Dekoven J,Parsons L,Pirzada S,Robern M,Robertson L,Tan JK.Biologic therapy in psoriasis: perspectives on associated risks and patient management.J Cutan Med Surg. 2012;16:153-68.